1. Protein tyrosine phosphatase nonreceptor type 2 controls colorectal cancer development
- Author
-
Katkeviciute, Egle, Hering, Larissa, Montalban-Arques, Ana, Busenhart, Philipp, Schwarzfischer, Marlene, Manzini, Roberto, Conde, Javier, Atrott, Kirstin, Lang, Silvia, Rogler, Gerhard, Naschberger, Elisabeth, Schellerer, Vera S., Sturzl, Michael, Rickenbacher, Andreas, Turina, Matthias, Weber, Achim, Leibl, Sebastian, Leventhal, Gabriel E., Levesque, Mitchell, Boyman, Onur, Scharl, Michael, and Spalinger, Marianne R.
- Subjects
Enzymes -- Regulation ,Colorectal cancer -- Genetic aspects -- Development and progression -- Care and treatment ,Esterases -- Health aspects ,Immunotherapy -- Methods -- Patient outcomes ,Health care industry - Abstract
Protein tyrosine phosphatase nonreceptor type 2 (PTPN2) recently emerged as a promising cancer immunotherapy target. We set out to investigate the functional role of PTPN2 in the pathogenesis of human colorectal carcinoma (CRC), as its role in immune-silent solid tumors is poorly understood. We demonstrate that in human CRC, increased PTPN2 expression and activity correlated with disease progression and decreased immune responses in tumor tissues. In particular, stage II and III tumors displayed enhanced PTPN2 protein expression in tumor-infiltrating T cells, and increased PTPN2 levels negatively correlated with expression of PD-1, CTLA4, STAT1, and granzyme A. In vivo, T cell- and DC-specific PTPN2 deletion reduced tumor burden in several CRC models by promoting [CD44.sup.+] effector/memory T cells, as well as [CD8.sup.+] T cell infiltration and cytotoxicity in the tumor. In direct relevance to CRC treatment, T cell-specific PTPN2 deletion potentiated anti-PD-1 efficacy and induced antitumor memory formation upon tumor rechallenge in vivo. Our data suggest a role for PTPN2 in suppressing antitumor immunity and promoting tumor development in patients with CRC. Our in vivo results identify PTPN2 as a key player in controlling the immunogenicity of CRC, with the strong potential to be exploited for cancer immunotherapy., Introduction Colorectal carcinoma (CRC) is the third most frequent malignancy and the second leading cause of cancer-related deaths worldwide (1, 2). In 2018, more than 1.8 million patients were newly [...]
- Published
- 2021
- Full Text
- View/download PDF